Sharp arrives at the company while maintaining his current position as a senior director at Lohman & Associates. His appointment brings significant industry experience to Cadrenal, following previous CFO tenures at Skye Bioscience, SaNOtize Research and Development, PhaseBioPharmaceuticals, and Ligand Pharmaceuticals. The company confirmed that the search for a permanent finance chief remains active.
Cadrenal Therapeutics Appoints John Sharp as Interim Finance Chief
John Sharp steps into the role of interim chief financial officer at Cadrenal Therapeutics, taking over the financial helm from Quang Pham. The transition arrives as the biopharmaceutical firm continues its hunt for a permanent executive to lead its fiscal strategy and long-term financial operations.
Comments (0)
No comments yet. Be the first!